Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of May 2025, with the report dated May 13, 2025. The filing discloses the entry into a material definitive agreement regarding a private securities offering.
Key Financial Metrics
The filing details a specific capital raise event rather than periodic financial performance metrics.
- Transaction Type: Sale and issuance of 200,000 Ordinary Shares.
- Gross Proceeds: Approximately $100,000 (before deducting offering expenses).
- Offering Status: Closed on May 12, 2025.
- Outstanding Shares: 16,027,758 Ordinary Shares as of May 12, 2025.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in outstanding share count and capital raised through the May 2025 offering. The transaction was executed pursuant to a prospectus supplement dated May 5, 2025, utilizing a takedown from the Company's effective shelf registration statement on Form F-3 (File No. 333-282776).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond standard legal disclaimers. It notes that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful without registration. The full terms of the Securities Purchase Agreement are referenced in Exhibit 10.1.
Investor Verification Checklist
- Verify the final net proceeds after deducting offering expenses, as only gross proceeds ($100,000) are stated.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific investor rights, vesting schedules, or covenants.
- Confirm the impact of the 200,000 new shares on existing shareholder dilution relative to the 16,027,758 outstanding shares.
- Check subsequent filings for the actual use of proceeds from this capital raise.